Physician profile
Orli Gal
NPI 1275254237
$887.86
in general payments reported to CMS, 2019-2025
18 companies · $15.20 in 2025
The $15.20 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $568 · 2024: $55.08 · 2025: $15.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.28 | 2023-2024 | |
| Novo Nordisk INC | $146.85 | 2022-2023 | Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $92.40 | 2022-2023 | |
| Harmony Biosciences LLC | $43.25 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $40.40 | 2023 | Breztri, Farxiga |
| Pfizer INC. | $35.81 | 2022 | |
| Corium, LLC | $35.60 | 2023 | Adlarity |
| Lilly USA, LLC | $34.30 | 2022-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.96 | 2022 | |
| Tandem Diabetes Care, INC. | $24.49 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Daiichi Sankyo INC. | $23.22 | 2023 | Injectafer |
| Dexcom, INC. | $21.96 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $19.55 | 2023 | Shingrix |
| Edwards Lifesciences Corporation | $18.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.43 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.29 | 2023 | Jornay Pm |
| Amgen INC. | $15.20 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $14.35 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orli Gal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.